Showing results (561-570 of 831) with videos related to
Sort By:
Pageof 84
American Journal of Hematology|April 13, 2017
Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance studyJeremy T Larsen, Tait D Shanafelt, Jose F Leis, et al.Cancer|January 31, 2018
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATEElias J Jabbour, Daniel J DeAngelo, Matthias Stelljes, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2006
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantationApostolia-Maria Tsimberidou, Susan O'Brien, Issa Khouri, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2009
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersenSusan O'Brien, Joseph O Moore, Thomas E Boyd, et al.Blood|February 1, 2003
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapyJorge E Cortes, Moshe Talpaz, Francis Giles, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicinFarhad Ravandi, Eli Estey, Dan Jones, et al.Blood|August 16, 2008
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemiaDeborah A Thomas, Susan O'Brien, Jeffrey L Jorgensen, et al.Blood|March 11, 2015
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemiaJennifer R Brown, Jacqueline C Barrientos, Paul M Barr, et al.Cancer Chemotherapy and Pharmacology|September 19, 2003
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemiaApostolia M Tsimberidou, Elihu Estey, Jorge E Cortes, et al.Leukemia & Lymphoma|March 1, 2022
Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphomaTanya Siddiqi, Steven Coutre, Matthew McKinney, et al.Pageof 84